GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Beneish M-Score

Predictive Oncology (Predictive Oncology) Beneish M-Score : -2.51 (As of Jun. 04, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.51 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Predictive Oncology's Beneish M-Score or its related term are showing as below:

POAI' s Beneish M-Score Range Over the Past 10 Years
Min: -29.81   Med: -3.12   Max: 11.66
Current: -2.51

During the past 13 years, the highest Beneish M-Score of Predictive Oncology was 11.66. The lowest was -29.81. And the median was -3.12.


Predictive Oncology Beneish M-Score Historical Data

The historical data trend for Predictive Oncology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Beneish M-Score Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.64 -3.02 -2.18 -3.79 -2.61

Predictive Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.11 -4.00 -3.29 -2.61 -2.51

Competitive Comparison of Predictive Oncology's Beneish M-Score

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Beneish M-Score falls into.



Predictive Oncology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Predictive Oncology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3132+0.528 * 0.9981+0.404 * 1.9525+0.892 * 1.3697+0.115 * 1.3222
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.684+4.679 * -0.143005-0.327 * 2.3776
=-2.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.51 Mil.
Revenue was 0.42 + 0.335 + 0.715 + 0.49 = $1.96 Mil.
Gross Profit was 0.232 + 0.087 + 0.608 + 0.33 = $1.26 Mil.
Total Current Assets was $6.56 Mil.
Total Assets was $10.60 Mil.
Property, Plant and Equipment(Net PPE) was $3.67 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.66 Mil.
Selling, General, & Admin. Expense(SGA) was $11.45 Mil.
Total Current Liabilities was $4.52 Mil.
Long-Term Debt & Capital Lease Obligation was $2.03 Mil.
Net Income was -4.219 + -3.475 + -3.163 + -3.923 = $-14.78 Mil.
Non Operating Income was 0.018 + 0.031 + -0.009 + -0.127 = $-0.09 Mil.
Cash Flow from Operations was -3.416 + -3.082 + -3.105 + -3.574 = $-13.18 Mil.
Total Receivables was $0.28 Mil.
Revenue was 0.24 + 0.363 + 0.456 + 0.372 = $1.43 Mil.
Gross Profit was 0.12 + 0.21 + 0.348 + 0.238 = $0.92 Mil.
Total Current Assets was $19.78 Mil.
Total Assets was $25.06 Mil.
Property, Plant and Equipment(Net PPE) was $4.83 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.23 Mil.
Selling, General, & Admin. Expense(SGA) was $12.22 Mil.
Total Current Liabilities was $3.91 Mil.
Long-Term Debt & Capital Lease Obligation was $2.60 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.509 / 1.96) / (0.283 / 1.431)
=0.259694 / 0.197764
=1.3132

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.916 / 1.431) / (1.257 / 1.96)
=0.640112 / 0.641327
=0.9981

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6.561 + 3.67) / 10.601) / (1 - (19.78 + 4.834) / 25.062)
=0.034902 / 0.017876
=1.9525

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.96 / 1.431
=1.3697

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.228 / (1.228 + 4.834)) / (0.664 / (0.664 + 3.67))
=0.202573 / 0.153207
=1.3222

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(11.445 / 1.96) / (12.217 / 1.431)
=5.839286 / 8.537386
=0.684

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.027 + 4.517) / 10.601) / ((2.597 + 3.91) / 25.062)
=0.6173 / 0.259636
=2.3776

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-14.78 - -0.087 - -13.177) / 10.601
=-0.143005

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Predictive Oncology has a M-score of -2.51 suggests that the company is unlikely to be a manipulator.


Predictive Oncology Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (Predictive Oncology) Business Description

Traded in Other Exchanges
N/A
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121